Novo Nordisk A/SNVONYSE
Loading
Net Income PerformanceStrong
Percentile Rank93
3Y CAGR+21.1%
5Y CAGR+18.5%
Studio
Year-over-Year Change

Total earnings after all expenses, taxes, and interest

3Y CAGR
+21.1%/yr
vs +9.5%/yr prior
5Y CAGR
+18.5%/yr
Consistent
Acceleration
+11.6pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
2.3x
Strong expansion
Streak
1 yr
Consecutive declineStrong
PeriodValueYoY Change
2025$98.50B-2.5%
2024$100.99B+20.7%
2023$83.68B+50.7%
2022$55.52B+16.3%
2021$47.76B+13.3%
2020$42.14B+8.2%
2019$38.95B+0.8%
2018$38.63B+1.3%
2017$38.13B+0.5%
2016$37.92B-